SCHEMBL10568366

SCHEMBL10568366

NNC(=O)C(O)(c1ccccc1)c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 4/20 0.51
LMNA P02545 2/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
CNR1 P21554 1/20 0.50
CNR2 P34972 1/20 0.50
ALDH1A1 P00352 4/20 0.46
GAA P10253 1/20 0.46
CYP2C9 P11712 1/20 0.45
PLK4 O00444 2/20 0.44
DAPK3 O43293 2/20 0.44
MAP4K4 O95819 2/20 0.44
PRKCG P05129 2/20 0.44
PIM1 P11309 2/20 0.44
PHKG2 P15735 2/20 0.44
CDK2 P24941 2/20 0.44
AXL P30530 2/20 0.44
AKT1 P31749 2/20 0.44
AKT2 P31751 2/20 0.44
SYK P43405 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10813682 0.83 HDAC1 (0.44) HTTLMNAL3MBTL1SMN1; SMN2CNR1
SCHEMBL5635835 0.80 KCNN4 (0.52) L3MBTL1HDAC3HDAC4HDAC1HDAC7
SCHEMBL2845025 0.80 HDAC3 (0.61) HTTLMNAL3MBTL1SMN1; SMN2CNR1
SCHEMBL15253649 0.79 AR (0.51) HTTLMNAL3MBTL1CNR1CNR2
SCHEMBL4620848 0.78 HTT (0.56) HTTLMNAL3MBTL1SMN1; SMN2CNR1
SCHEMBL10815988 0.78 MAPT (0.47) HTTLMNAL3MBTL1SMN1; SMN2HDAC3
SCHEMBL21378779 0.77 MAPT (0.61) CNR1CNR2HDAC3HDAC4HDAC1
SCHEMBL30594253 0.77 PDK1 (0.55) HTTLMNAL3MBTL1SMN1; SMN2CNR1
SCHEMBL8671312 0.77 GAA (0.53) HTTLMNAL3MBTL1SMN1; SMN2CNR1
SCHEMBL4377312 0.77 CYP1A2 (0.48) HTTLMNAL3MBTL1SMN1; SMN2CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260014080-A1 LIPOSOMAL PREPARATION WITH ENCAPSULATED HORMONES, METHOD OF PRODUCTION AND USE THEREOF VAN BOGAERT GINA (BE) 2026-01-15 US disclosed
US-20230248742-A1 PHARMACEUTICAL COMPOSITIONS OF TESTOSTERONE SLAYBACK PHARMA LLC (US) 2023-08-10 US disclosed
US-11642355-B2 Pharmaceutical compositions of testosterone SLAYBACK PHARMA LLC (US) 2023-05-09 US disclosed
US-20220202830-A1 PHARMACEUTICAL COMPOSITIONS OF TESTOSTERONE SLAYBACK PHARMA LLC (US) 2022-06-30 US disclosed
US-11311554-B2 Pharmaceutical compositions of testosterone SLAYBACK PHARMA LLC (US) 2022-04-26 US disclosed
CN-110724124-A Triazole derivatives 株式会社半导体能源研究所 2020-01-24 CN disclosed
US-20190307772-A1 PHARMACEUTICAL COMPOSITIONS OF TESTOSTERONE SLAYBACK PHARMA LLC (US) 2019-10-10 US disclosed
CN-101542370-A Fine particle dispersion liquid NATOCO CO LTD (JP) 2009-09-23 CN disclosed
US-4883907-A Carbazates EGIS GYOGYSZERGYAR (HU) 1989-11-28 US disclosed
US-4824670-A ANIMAL FEEDS EGIS GYOGYSZERGYAR (HU) 1989-04-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230248742-A1 PHARMACEUTICAL COMPOSITIONS OF TESTOSTERONE SHBG, CYP17A1, NR5A1 HTT 368/4885LMNA 793/4885L3MBTL1 2261/4885
US-11311554-B2 Pharmaceutical compositions of testosterone SHBG, CYP17A1, NR5A1 HTT 419/4885LMNA 828/4885L3MBTL1 2423/4885
US-11642355-B2 Pharmaceutical compositions of testosterone SHBG, CYP17A1, NR5A1 HTT 396/4885LMNA 800/4885L3MBTL1 2328/4885
US-20260014080-A1 LIPOSOMAL PREPARATION WITH ENCAPSULATED HORMONES, METHOD OF PRODUCTION AND USE THEREOF NR5A1, SHBG, GNRHR HTT 1672/4885LMNA 796/4885L3MBTL1 2588/4885
US-20190307772-A1 PHARMACEUTICAL COMPOSITIONS OF TESTOSTERONE SHBG, CYP17A1, NR5A1 HTT 419/4885LMNA 828/4885L3MBTL1 2423/4885
US-20220202830-A1 PHARMACEUTICAL COMPOSITIONS OF TESTOSTERONE SHBG, CYP17A1, NR5A1 HTT 396/4885LMNA 800/4885L3MBTL1 2328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.